Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
University of Pittsburgh
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Palleon Pharmaceuticals, Inc.
Memorial Sloan Kettering Cancer Center
Genentech, Inc.
NGM Biopharmaceuticals, Inc
Revolution Medicines, Inc.
Arbeitsgemeinschaft medikamentoese Tumortherapie
Stanford University
Xencor, Inc.
Cedars-Sinai Medical Center
Rutgers, The State University of New Jersey
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Klus Pharma Inc.
Revolution Medicines, Inc.
Eastern Cooperative Oncology Group
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Pfizer
Incyte Corporation
MacroGenics
BioNTech SE
Abramson Cancer Center at Penn Medicine
Celgene
Swiss Cancer Institute
Wake Forest University Health Sciences
Santa Maria Biotherapeutics
Celldex Therapeutics
Memorial Sloan Kettering Cancer Center
OHSU Knight Cancer Institute
Merck Sharp & Dohme LLC
INSYS Therapeutics Inc
University of Chicago
Dartmouth-Hitchcock Medical Center
Altor BioScience
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Netherlands Open University
Case Comprehensive Cancer Center